Abstract | OBJECTIVES: METHODS: Pharmacokinetic studies were performed in guinea pigs to establish human-equivalent doses of thioridazine. Guinea pigs were aerosol-infected with ∼100 bacilli of Mycobacterium tuberculosis and single- drug treatment was started 4 weeks later with a range of thioridazine doses daily (5 days/week) for up to 4 weeks. Control animals received no treatment or 60 mg/kg isoniazid. RESULTS: The human-equivalent dose of thioridazine was determined to be 5 mg/kg with saturable absorption noted above 50 mg/kg. At the start of treatment, the lung bacterial burden was ∼6.2 log10 cfu. Although isoniazid reduced bacillary counts more than 10-fold, thioridazine monotherapy showed limited killing over the range of doses tested, reducing lung bacillary counts by 0.3-0.5 log10 following 1 month of treatment. Thioridazine was tolerated up to 40 mg/kg. CONCLUSIONS:
|
Authors | Noton K Dutta, Michael L Pinn, Ming Zhao, Michelle A Rudek, Petros C Karakousis |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 68
Issue 6
Pg. 1327-30
(Jun 2013)
ISSN: 1460-2091 [Electronic] England |
PMID | 23463208
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aerosols
- Antipsychotic Agents
- Thioridazine
|
Topics |
- Aerosols
- Animals
- Antipsychotic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Area Under Curve
- Dose-Response Relationship, Drug
- Endpoint Determination
- Extracellular Space
- Female
- Guinea Pigs
- Humans
- Mice
- Mycobacterium tuberculosis
(drug effects)
- Organ Size
(drug effects)
- Thioridazine
(adverse effects, pharmacokinetics, therapeutic use)
- Tuberculosis
(drug therapy, microbiology, pathology)
|